WHO ICTRP trial
Recombinant endostatin (Sulijia) combined chemotherapy with Vinorelbine and…
ChiCTR-TRC-11001539 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-TRC-11001539 |
|---|---|
| Public title | Recombinant endostatin (Sulijia) combined chemotherapy with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III trial |
| Scientific title | Recombinant endostatin ( Sulijia) combined chemotherapy with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III trial |
| Primary sponsor | Cancer Institute & Hospital Chinese Academy of Medical Science |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | III (Phase III study) |
| Countries | China |
| Conditions | Advanced or metastatic (IV) NSCLC |
| Interventions | Control group:Placebo combined chemotherapy with Vinorelbine and Cisplatin (NP);Experimental group:Sulijia combined chemotherapy with Vinorelbine and Cisplatin (NP) |
| Registration date | Aug 12, 2011 |
| Target size | Control group:184;Experimental group:376 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: